Investigators Testing Ways To Overcome Gleevec Resistance: High Dose, New Drugs
FDA Approves Abraxane For Second-Line Treatment Of Metastatic Breast Cancer
New Regimens May Benefit Multiple Myeloma Patients
Two New Modalities Promising For Relapsed/Refractory NHL
Amgen’s Kepivance Approved For Severe Oral Mucositis
Clolar Approved for Pediatric Refractory/Relapsed ALL
Blacks Half As Likely To Get Surgery For Esophageal Cancer
NCI-Approved Clinical Trials Listed For January
Trending Stories
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures - In weekly vigils, current and former NIH staff grieve the impact of Trump cuts
The Saturday gatherings at NIH’s Metro station are part graveside service, part street theater - She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research
- Scaling excellence: How City of Hope is transforming cancer care delivery
- First-ever financial toxicity tumor board aims to change the standard of care
Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI